Go Pro
OTCMKTS:PURE

PURE Bioscience (PURE) Stock Price, News & Analysis

PURE Bioscience logo
$0.06 0.00 (-2.28%)
As of 08/25/2026 02:16 PM Eastern

About PURE Bioscience Stock (OTCMKTS:PURE)

Advanced

Key Stats

Today's Range
$0.06
$0.06
50-Day Range
$0.06
$0.09
52-Week Range
$0.04
$0.11
Volume
4,860 shs
Average Volume
32,109 shs
Market Capitalization
$7.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

PURE Bioscience, Inc. is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions. Its food safety line offers surface sanitizers and processing aids approved by the U.S. Department of Agriculture (USDA) and the Food and Drug Administration (FDA) for direct contact with food-contact surfaces. The company also supplies biocidal chemistries for incorporation into personal care products such as shampoos and topical washes, as well as specialty solutions for water disinfection.

Founded in 2001, PURE Bioscience holds a portfolio of patents covering the generation and stabilization of SDC, which it licenses globally through distribution partnerships. The company serves customers across North America, with growing penetration into international markets via strategic alliances. PURE continues to expand its product approvals and registrations, reinforcing its position in regulated sectors that require validated antimicrobial efficacy.

PURE’s leadership team combines expertise in microbiology, regulatory affairs, and commercial operations to guide product development and market expansion. By focusing on scalable manufacturing processes, rigorous quality controls, and regulatory compliance, PURE Bioscience aims to address evolving public health needs with science-driven antimicrobial solutions.

AI Generated. May Contain Errors.

PURE Bioscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
3rd Percentile Overall Score

PURE MarketRank™: 

PURE Bioscience scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for PURE Bioscience.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PURE Bioscience is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PURE Bioscience is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.01% of the float of PURE Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    PURE Bioscience has a short interest ratio ("days to cover") of 0.21, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PURE Bioscience has recently increased by 30.50%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    PURE Bioscience does not currently pay a dividend.

  • Dividend Growth

    PURE Bioscience does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for PURE Bioscience this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, PURE Bioscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    35.56% of the stock of PURE Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    PURE Bioscience has minimal institutional ownership at this time.

  • Read more about PURE Bioscience's insider trading history.
Receive PURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PURE Bioscience and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PURE Stock News Headlines

Pure Bioscience Inc.
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Chaikin Money Flow indicator has a new top retirement pick. The company holds three fast-growing businesses -- including an autonomous vehicle unit and a streaming service with 10x Netflix's reach -- any of which could be spun off in the next 12 to 24 months. It also pays a dividend, a rarity among high-growth AI names. Chaikin lays out the full case in a new free presentation, no email or credit card required.tc pixel
See More Headlines

PURE Stock Analysis - Frequently Asked Questions

PURE Bioscience's stock was trading at $0.0420 at the beginning of 2026. Since then, PURE stock has increased by 42.9% and is now trading at $0.06.

PURE Bioscience (OTCMKTS:PURE) issued its earnings results on Monday, June, 15th. The company reported ($0.01) EPS for the quarter. The business earned $0.51 million during the quarter.

Shares of PURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PURE Bioscience investors own include Meta Platforms (META), Hydrofarm Holdings Group (HYFM), Twilio (TWLO), NVIDIA (NVDA), Enphase Energy (ENPH) and Novavax (NVAX).

Company Calendar

Last Earnings
6/15/2026
Today
8/25/2026
Fiscal Year End
7/31/2027

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Healthcare Equipment & Supplies
Sub-Industry
N/A
Current Symbol
OTCMKTS:PURE
CIK
1006028
Employees
10
Year Founded
1992

Profitability

EPS (Trailing Twelve Months)
($0.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.40 million
Net Margins
-109.59%
Pretax Margin
-65.45%
Return on Equity
N/A
Return on Assets
-321.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.42
Quick Ratio
0.36

Sales & Book Value

Annual Sales
$2.20 million
Price / Sales
3.55
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.05) per share
Price / Book
-1.20

Miscellaneous

Outstanding Shares
130,020,000
Free Float
83,784,000
Market Cap
$7.80 million
Optionable
Not Optionable
Beta
0.21

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (OTCMKTS:PURE) was last updated on 8/26/2026 by MarketBeat.com Staff.
From Our Partners